SC
PRTK

Scholtz & Company’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Scholtz & Company’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,195
Closed -$88K – 81
2020
Q3 		$88K Sell
16,195
-7,300
-31% -$36.1K 0.04% 68
2020
Q2 		$123K Buy
+23,495
New +$104K 0.06% 59

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Scholtz & Company's PRTK Position: Q4 2020 in Review

Scholtz & Company sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2020, closing a stake of 16,195 shares — an estimated $88K sold.

Scholtz & Company first reported a position in PRTK in Q2 2020 and held it in 2 quarters. The position peaked at $123K in Q2 2020. 108 funds tracked by Wall St. Rank hold PRTK as of Q4 2020.

  • Scholtz & Company reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Scholtz & Company sold 16,195 Paratek Pharmaceuticals, Inc. shares in Q4 2020, an estimated $88K.
  • Scholtz & Company first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2020 and held it in 2 quarters.
  • Scholtz & Company's Paratek Pharmaceuticals, Inc. position peaked at $123K in Q2 2020.
  • 108 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2020.

Based on Scholtz & Company's 13F filing for Q4 2020, filed 12 Feb 2021.